Interim Safety and Efficacy Outcomes of an Open-Label Long-Term Extension Study of Treatment with PI3Kδ Inhibitor Leniolisib in Pediatric Patients Aged 4-11 Years with Activated PI3Kδ Syndrome (APDS)
Artículo
Material complementario disponible
Artículo
DOAJ
Leniolisib, a selective PI3Kδ inhibitor, is a Food and Drug Administration (FDA)-approved treatment for activated PI3Kδ syndrome (APDS) in patients ≥12 years weighing ≥45 kg. To determine its impact on children, pa...
LCC LCC:Immunologic diseases. AllergyIdioma eng
Material complementario disponibleEl enlace apunta a material asociado, anexos, tablas, datos o página complementaria. No se marca como libro/texto completo.
Material complementario